KLDO (Kaleido Biosciences) PS Ratio: 0.00 (As of Jul. 05, 2026)


What is Kaleido Biosciences PS Ratio?

Kaleido Biosciences KLDO -99.00% PS Ratio is 0.00 as of Jul. 05, 2026.

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Kaleido Biosciences's share price is $0.0001. Kaleido Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 was $0.03. Hence, Kaleido Biosciences's PS Ratio for today is 0.00.

The historical rank and industry rank for Kaleido Biosciences's PS Ratio or its related term are showing as below:

KLDO's PS Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 9.93
* Ranked among companies with meaningful PS Ratio only.

Kaleido Biosciences's Revenue per Sharefor the three months ended in Dec. 2021 was $0.01. Its Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 was $0.03.

Back to Basics: PS Ratio


Kaleido Biosciences  (OTCPK:KLDO) PS Ratio Explanation

The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.

When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.

Similar to the PE Ratio or Price-to-Operating-Cash-Flow or Price-to-Free-Cash-Flow , the PS Ratio measures the valuation based on the earning power of the company. This is where it is different from the PB Ratio , which measures the valuation based on the company's balance sheet.


Be Aware

The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.


Kaleido Biosciences PS Ratio Related Terms


Kaleido Biosciences PS Ratio Historical Data

* Premium members only.

The historical data trend for Kaleido Biosciences's PS Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Kaleido Biosciences PS Ratio Chart

Kaleido Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
PS Ratio
Get a 7-Day Free Trial 0.00 0.00 0.00 313.79 91.92

Kaleido Biosciences Quarterly Data
Dec16 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21
PS Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 313.79 225.00 225.45 260.00 91.92

KLDO vs NPTX, GSTC, BZYR: PS Ratio Comparison

For the Biotechnology subindustry, Kaleido Biosciences's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kaleido Biosciences PS Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Kaleido Biosciences's PS Ratio distribution charts can be found below:

* The bar in red indicates where Kaleido Biosciences's PS Ratio falls into.



Kaleido Biosciences PS Ratio Calculation

The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.

Kaleido Biosciences's PS Ratio for today is calculated as

PS Ratio=Share Price/Revenue per Share (TTM)
=0.0001/0.026
=0.00

Kaleido Biosciences's Share Price of today is $0.0001.
Kaleido Biosciences's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2021 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.03.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

PS Ratio=Market Cap/Revenue

The Revenue here is for the trailing 12 months.

Frequently Asked Questions Learn more about PS Ratio →
What does a PS Ratio of 0.00 mean?
Kaleido Biosciences (KLDO) has a PS Ratio of 0.00 as of Jul. 05, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Kaleido Biosciences and its competitors.
Is Kaleido Biosciences' PS Ratio too high?
Kaleido Biosciences' current PS Ratio is 0.00.
How does Kaleido Biosciences' PS Ratio compare to NPTX and GSTC?
Kaleido Biosciences' PS Ratio of 0.00 can be compared against companies in the Biotechnology industry. The industry median PS Ratio is 9.93. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.93, based on 931 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Kaleido Biosciences and its competitors. For the Biotechnology industry, the median PS Ratio is 9.93 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kaleido Biosciences's current PS Ratio is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kaleido Biosciences stock overvalued right now?
Kaleido Biosciences (KLDO) has a current PS Ratio of 0.00. The current PS Ratio is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Kaleido Biosciences (KLDO), the current PS Ratio is 0.00 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Kaleido Biosciences Business Description

Address 65 Hayden Avenue, Lexington, MA, USA, 02421
Kaleido Biosciences Inc is a clinical-stage healthcare company. It is focused on leveraging the potential of the microbiome organ to treat disease and improve human health. Its product candidates are Microbiome Metabolic Therapies, or MMTs, which are designed to modulate the metabolic output and profile of the microbiome.